A combination of tenofovir and emtricitabine suppressed hepatitis B virus replication more than tenofovir alone over 4 years for people with inactive or immune-tolerant disease, researchers reported at the EASL International Liver Congress this week in Amsterdam.
http://www.hivandhepatitis.com/hepatitis-b/hepatitis-b-topics/hbv-treatment/4085-easl-2013-truvada-works-best-for-immune-tolerant-hepatitis-b-patients-but-do-they-need-treatment
http://www.hivandhepatitis.com/hepatitis-b/hepatitis-b-topics/hbv-treatment/4085-easl-2013-truvada-works-best-for-immune-tolerant-hepatitis-b-patients-but-do-they-need-treatment
No comments:
Post a Comment